SEARCH

SEARCH BY CITATION

References

  • 1
    Vogel AM, Lennon DR, Broadbent R et al. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants. J. Paediatr. Child Health 2002; 38: 5504.
  • 2
    Thomas M, Bedford-Russell A, Sharland M. Prevention of respiratory syncytial virus infection with palivizumab. Monaldi Arch. Chest Dis. 2000; 55: 3338.
  • 3
    Thomas M, Bedford-Russell A, Sharland M. Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin. Arch. Dis. Child. 2000; 83: 1227.
  • 4
    Joffe SEG, Black SB, Armstrong MA, Lieu TA. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics 1999; 104: 8949.
  • 5
    Vogel AM, McKinlay MJ, Ashton T et al. Cost-effectiveness of palivizumab in New Zealand. J. Paediatr. Child Health 2002; 38: 3527.
  • 6
    Impact Respiratory Syncytial Virus Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 5317.
  • 7
    Numa A. Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis. J. Paediatr. Child Health 2000; 36: 4227.
  • 8
    Abbott UK. Guidance for the Use of Synagis. 1999; Abbott Laboratories, Berkshire.
  • 9
    Marcovitch H. Palivizumab and RSV prophylaxis. Arch. Dis. Child. 2000; 83: 88.